444 related articles for article (PubMed ID: 22075757)
1. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
Wei Y; Zhang Z; Liao H; Wu L; Wu X; Zhou D; Xi X; Zhu Y; Feng Y
Oncol Rep; 2012 Feb; 27(2):504-10. PubMed ID: 22075757
[TBL] [Abstract][Full Text] [Related]
2. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
[TBL] [Abstract][Full Text] [Related]
3. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
Tsai CL; Wu HM; Lin CY; Lin YJ; Chao A; Wang TH; Hsueh S; Lai CH; Wang HS
PLoS One; 2013; 8(9):e72999. PubMed ID: 24039841
[TBL] [Abstract][Full Text] [Related]
4. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway.
Zhang J; Yang Y; Zhang Z; He Y; Liu Z; Yu Y; Wu S; Cai B; Feng Y
Cancer Lett; 2013 Oct; 339(2):279-87. PubMed ID: 23142288
[TBL] [Abstract][Full Text] [Related]
5. The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRγ through AKT and ERK1/2.
Sun Y; Wang C; Yang H; Ma X
Eur J Cancer Prev; 2014 Sep; 23(5):418-24. PubMed ID: 25068805
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
Block M; Fister S; Emons G; Seeber S; Gründker C; Günthert AR
Anticancer Res; 2010 Jun; 30(6):2025-31. PubMed ID: 20651347
[TBL] [Abstract][Full Text] [Related]
7. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
8. 17β-Estradiol on the Expression of G-Protein Coupled Estrogen Receptor (GPER/GPR30) Mitophagy, and the PI3K/Akt Signaling Pathway in ATDC5 Chondrocytes In Vitro.
Fan DX; Yang XH; Li YN; Guo L
Med Sci Monit; 2018 Apr; 24():1936-1947. PubMed ID: 29608013
[TBL] [Abstract][Full Text] [Related]
9. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells.
Guo RX; Wei LH; Tu Z; Sun PM; Wang JL; Zhao D; Li XP; Tang JM
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):9-18. PubMed ID: 16567092
[TBL] [Abstract][Full Text] [Related]
10. [Influence of pertussis toxin on GPER-mediated activation of phosphatidylinositol 3-kinase/protein kinase B signaling induced by 17β-estradiol in endometrial carcinoma cells].
Guo RX; Lei J; Wang XY; Ge X; Hu DM; Ma XY; Li LX; Qiao YH
Zhonghua Fu Chan Ke Za Zhi; 2013 Feb; 48(2):129-33. PubMed ID: 23544495
[TBL] [Abstract][Full Text] [Related]
11. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.
He YY; Cai B; Yang YX; Liu XL; Wan XP
Cancer Sci; 2009 Jun; 100(6):1051-61. PubMed ID: 19432902
[TBL] [Abstract][Full Text] [Related]
12. Bisphenol A and estrogen induce proliferation of human thyroid tumor cells via an estrogen-receptor-dependent pathway.
Zhang Y; Wei F; Zhang J; Hao L; Jiang J; Dang L; Mei D; Fan S; Yu Y; Jiang L
Arch Biochem Biophys; 2017 Nov; 633():29-39. PubMed ID: 28882636
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Chen Y; Li Z; He Y; Shang D; Pan J; Wang H; Chen H; Zhu Z; Wan L; Wang X
Toxicol Appl Pharmacol; 2014 Mar; 275(2):176-81. PubMed ID: 24440569
[TBL] [Abstract][Full Text] [Related]
14. [Effect of GPER on the activation of PI3K/Akt induced by 17β-estradiol in endometrial carcinoma cells].
Zhang YC; Guo RX; Ge X; Qiao YH
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):292-6. PubMed ID: 22781117
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells.
Zhang H; Wang X; Chen Z; Wang W
Cell Mol Biol (Noisy-le-grand); 2015 Nov; 61(7):96-101. PubMed ID: 26638889
[TBL] [Abstract][Full Text] [Related]
16. LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1.
Chen C; Wang Y; Wang S; Liu Y; Zhang J; Xu Y; Zhang Z; Bao W; Wu S
Int J Oncol; 2017 Mar; 50(3):942-952. PubMed ID: 28098854
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
18. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Filardo EJ; Quinn JA; Frackelton AR; Bland KI
Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440
[TBL] [Abstract][Full Text] [Related]
19. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
[TBL] [Abstract][Full Text] [Related]
20. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells.
Vivacqua A; Romeo E; De Marco P; De Francesco EM; Abonante S; Maggiolini M
Breast Cancer Res Treat; 2012 Jun; 133(3):1025-35. PubMed ID: 22147081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
